"Cholesterol, LDL" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cholesterol which is contained in or bound to low density lipoproteins (LDL), including CHOLESTEROL ESTERS and free cholesterol.
| Descriptor ID |
D008078
|
| MeSH Number(s) |
D04.210.500.247.808.197.244 D10.532.515.500 D10.570.938.208.275 D12.776.521.550.500
|
| Concept/Terms |
Cholesterol, LDL- Cholesterol, LDL
- Low Density Lipoprotein Cholesterol
- beta-Lipoprotein Cholesterol
- Cholesterol, beta-Lipoprotein
- beta Lipoprotein Cholesterol
- LDL Cholesterol
|
Below are MeSH descriptors whose meaning is more general than "Cholesterol, LDL".
Below are MeSH descriptors whose meaning is more specific than "Cholesterol, LDL".
This graph shows the total number of publications written about "Cholesterol, LDL" by people in this website by year, and whether "Cholesterol, LDL" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 2 | 2 |
| 1997 | 1 | 3 | 4 |
| 1998 | 2 | 0 | 2 |
| 1999 | 1 | 6 | 7 |
| 2000 | 1 | 5 | 6 |
| 2001 | 1 | 6 | 7 |
| 2002 | 2 | 6 | 8 |
| 2003 | 2 | 11 | 13 |
| 2004 | 1 | 7 | 8 |
| 2005 | 4 | 8 | 12 |
| 2006 | 6 | 7 | 13 |
| 2007 | 4 | 6 | 10 |
| 2008 | 7 | 4 | 11 |
| 2009 | 5 | 6 | 11 |
| 2010 | 2 | 10 | 12 |
| 2011 | 10 | 16 | 26 |
| 2012 | 3 | 15 | 18 |
| 2013 | 11 | 15 | 26 |
| 2014 | 12 | 14 | 26 |
| 2015 | 8 | 10 | 18 |
| 2016 | 10 | 14 | 24 |
| 2017 | 5 | 11 | 16 |
| 2018 | 8 | 9 | 17 |
| 2019 | 13 | 14 | 27 |
| 2020 | 6 | 10 | 16 |
| 2021 | 8 | 10 | 18 |
| 2022 | 1 | 23 | 24 |
| 2023 | 0 | 20 | 20 |
| 2024 | 4 | 13 | 17 |
| 2025 | 4 | 9 | 13 |
| 2026 | 0 | 4 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cholesterol, LDL" by people in Profiles.
-
Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial. Nat Med. 2026 Mar; 32(3):1052-1060.
-
The evolving therapeutic landscape of PCSK9 inhibition. Atherosclerosis. 2026 Mar; 414:120670.
-
The impact of genetic testing on physician practice in specialized cardiovascular clinics. J Clin Lipidol. 2026 Mar; 20(3):677-681.
-
Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial. JAMA. 2026 01 13; 335(2):129-139.
-
Zodasiran, an RNAi therapeutic targeting ANGPTL3, for treating patients with homozygous familial hypercholesterolaemia (GATEWAY): an open-label, randomised, phase 2 trial. Lancet Diabetes Endocrinol. 2026 Feb; 14(2):123-136.
-
The evolving landscape of targets for lipid lowering: from molecular mechanisms to translational implications. Eur Heart J. 2025 Nov 21; 46(44):4737-4750.
-
Lipid profile and the variables associated with control of selected lipid parameters in patients of a large multi-specialist hospital in Poland - the Jurasz Lipid Study (JLS). Lipids Health Dis. 2025 Sep 29; 24(1):300.
-
Impact of Obicetrapib on Major Adverse Cardiovascular Events in High-Risk Patients: A Pooled Analysis. J Am Coll Cardiol. 2025 Oct 07; 86(14):1046-1056.
-
Simulation model to estimate pretreatment (baseline) low-density lipoprotein cholesterol levels in people living with homozygous familial hypercholesterolemia. J Clin Lipidol. 2025 Sep-Oct; 19(5):1457-1462.
-
Rationale and design of the REMBRANDT trial: A phase 3 study to evaluate the effect of obicetrapib/ezetimibe on coronary plaque characteristics. Am Heart J. 2025 Dec; 290:325-338.